Patients with type 1 diabetes require exogenous insulin to control blood glucose levels and to help prevent or reduce the onset of serious diabetic complications. Conventional insulin therapy involves multiple, daily, subcutaneous injections or use of an external insulin pump that delivers insulin via a subcutaneous catheter. Recently, insulin delivery systems that can deliver short-acting insulin via oral inhalation have been developed with the goal of reducing the number of insulin injections required.